London, United Kingdom (PressExposure) July 28, 2011 -- Drug-eluting Balloons (DEB) are one of the most successful technologies to emerge in the cardiovascular market in recent years. DEBs have introduced a new dimension to the way coronary and peripheral artery diseases are treated, and the greater adoption of this technology is bound to have a substantial impact on the interventional cardiovascular devices market.
It is estimated that that about 1.1 million percutaneous stenting procedures are done across the globe and approximately 25% of these patients suffer from In Stent Restenosis (ISR). The use of DEBs in this population is expected to drive the growth of the DEB market in the coming years.
DEBs are anti-restenotic drug coated PTCA (Percuatneous Transluminal Coronary Angioplasty) balloons which are intended to prevent the renarrowing of the coronary artery after stent placement. They are designed for intraluminal drug application in coronary arteries and peripheral vessels to treat ISR, bifurcations, small vessels, and long lesions. The use of drug-coated balloons appears to hold promise as a viable alternative to stand-alone balloon angioplasty and stent implantation for the treatment of coronary and peripheral arterial disease.
The global market for DEBs was $104.6m in 2010 and is forecast to reach $178m in 2017. Driven by positive results from various previous and ongoing clinical trials the acceptance of DEB as a suitable treatment option is increasing.
The major companies that market DEBs are B Braun (SeQuent Please), Medtronic (IN.PACT, with Invatec's acquisition) and Eurocor (DIOR).
For Sample Pages, please click or add the below link to your browser:
DEB as a technology is known to be much simpler and less invasive than other treatment options and has the potential to create interest among interventional surgeons to be used in niche populations for treating ISR and bifurcation lesions.
Magnetic Resonance Imaging (MRI) compatible devices are expected to experience a high adoption rate by surgeons and are expected to be the mainstay in cardiac rhythm management (CRM) over the years.
Conventional implantable devices for CRM do not offer compatibility with MRI, which is of importance in diagnosing events like stroke, cancer, problems with the spinal cord and brain and other conditions. There are about four million patients worldwide with pacemakers and over 75% of them require an MRI scan. About 20,000 patients in the US annually forego MRIs as they have a pacemaker implanted. This is an unmet need that many companies are trying to address through developing MRI compatible pacemakers that would allow patients with implanted devices to safely undergo required diagnostic imaging tests.
GBI Research's report, "Emerging Medical Devices Technology Trends - 2011" provides information and analysis on the various emerging technologies in the medical devices industry. The report provides description of the technology, likely impact of the technology from market point of view, key players developing or already marketing the technology and details of pipeline products of few of the technologies.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.gbiresearch.com
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782